{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:14:13Z","timestamp":1770902053759,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.seizure.2018.03.003","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T02:03:20Z","timestamp":1520474600000},"page":"76-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Time course of reversal of valproate-mediated inhibition of lamotrigine"],"prefix":"10.1016","volume":"57","author":[{"given":"Emili","family":"Leary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3966-5643","authenticated-orcid":false,"given":"Raj D.","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry E.","family":"Gidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2018.03.003_bib0005","unstructured":"Lamictal [package insert], Research Triangle Park, NC:GlaxoSmithKline, 2015."},{"issue":"2\u20133","key":"10.1016\/j.seizure.2018.03.003_bib0010","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eplepsyres.2003.09.008","article-title":"Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy","volume":"57","author":"Gidal","year":"2003","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.seizure.2018.03.003_bib0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF03191157","article-title":"Lamotrigine and valproate pharmacokinetics interactions in epileptic patients","volume":"34","author":"Lalic","year":"2009","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"10.1016\/j.seizure.2018.03.003_bib0020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00007691-199904000-00008","article-title":"Lamotrigine plasma concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications","volume":"21","author":"Armijo","year":"1999","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.seizure.2018.03.003_bib0025","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0009-9236(96)90130-7","article-title":"Bidirectional interaction of valproate and lamotrigine in healthy subjects","volume":"60","author":"Anderson","year":"1996","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.seizure.2018.03.003_bib0030","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003088-199529040-00005","article-title":"Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. part I: phenobarbital, primidone, valproic avid, ethosuximide and mesuximide","volume":"29","author":"Battino","year":"1995","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.seizure.2018.03.003_bib0035","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FTD.0b013e31825ee389","article-title":"Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication","volume":"34","author":"Johannessen Landmark","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2018.03.003_bib0040","article-title":"Effect of age-related factors on the pharmacokinetics of lamotrigine and potential implications for dose optimization in epilepsy patients","author":"Van Dijkman","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.seizure.2018.03.003_bib0045","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2125.1992.tb04079.x","article-title":"Sodium valproate acutely inhibits lamotrigine metabolism","volume":"33","author":"Yuen","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2018.03.003_bib0050","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.dmpk.2015.01.001","article-title":"Influence of uridine diphosphate glucuronosyltransferase inducers and inhibitors on the plasma lamotrigine concentration in pediatric patients with refractory epilepsy","volume":"30","author":"Yamamoto","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.seizure.2018.03.003_bib0055","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bcp.12984","article-title":"Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: influence of polymorphism of UDP-glucuronyltransferases and drug transporters","volume":"82","author":"Milosheska","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2018.03.003_bib0060","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1528-1167.2006.00423.x","article-title":"Predictors of lamotrigine-associated rash","volume":"47","author":"Hirsch","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.03.003_bib0065","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3805\/eands.8.21","article-title":"Appropriate conversion from valproate monotherapy to lamotrigine monotherapy in Japanese women with epilepsy","volume":"8","author":"Yamamoto","year":"2016","journal-title":"Epilepsy Seizure"},{"key":"10.1016\/j.seizure.2018.03.003_bib0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.yebeh.2004.11.002","article-title":"A dosing algorithm for converting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy","volume":"6","author":"Sale","year":"2005","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.seizure.2018.03.003_bib0075","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","article-title":"In vitro characterization of lamotrigine n2-glucoronidation and the lamotrigine-valproic acid interaction","volume":"34","author":"Rowland","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.seizure.2018.03.003_bib0080","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.dmpk.2014.12.001","article-title":"A comprehensive review of UDP-glucuronsyltransferase and esterases for drug development","volume":"30","author":"Oda","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"issue":"1","key":"10.1016\/j.seizure.2018.03.003_bib0085","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/dmd.108.022426","article-title":"Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10","volume":"37","author":"Argikar","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.seizure.2018.03.003_bib0090","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.metabol.2006.01.006","article-title":"N-glucuronidation of the antiepileptic drug ezogabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney and liver microsomal membranes of Crigler-Najjar type II","volume":"55","author":"Borlak","year":"2006","journal-title":"Metabol Clin Exp"},{"issue":"5","key":"10.1016\/j.seizure.2018.03.003_bib0095","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0090-9556(24)15257-9","article-title":"Ezogabine N-glucuronidation and its potential role in enterohepatic circulation","volume":"27","author":"Hiller","year":"1999","journal-title":"Drug Metab Distrib"},{"key":"10.1016\/j.seizure.2018.03.003_bib0100","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1124\/dmd.113.051656","article-title":"The glucuronidation of R- and S-lorazepam: human liver microsomal kinetics, UDP-glucuronosyltransferase enzyme selectivity, and inhibition by drugs","volume":"41","author":"Uchaipichat","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.seizure.2018.03.003_bib0105","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1528-1157.1994.tb02937.x","article-title":"Wilensky Lorazepam-valproate interaction: studies in normal subjects and isolated perfused rat liver","volume":"35","author":"Anderson","year":"1994","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2018.03.003_bib0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FTD.0b013e3181ceecc6","article-title":"UGT2B7_-161C > T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study","volume":"32","author":"Blanca-Sanchez","year":"2010","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.seizure.2018.03.003_bib0115","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/FTD.0000000000000012","article-title":"Influence of Uridine diphosphate glucuronosyltransferase 2B7-161C > T polymorphism on the concentration of valproic acid in pediatric epilepsy patients","volume":"36","author":"Inoue","year":"2014","journal-title":"Ther Drug Monit"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131117308361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131117308361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:50:33Z","timestamp":1761011433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131117308361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":23,"alternative-id":["S1059131117308361"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2018.03.003","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time course of reversal of valproate-mediated inhibition of lamotrigine","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2018.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}